SILVERCREST ASSET MANAGEMENT GROUP LLC
Position in RYTM — Rhythm Pharmaceuticals, Inc.
CIK 1232395
NEW YORK, NY
Position in RYTM
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$4,077,762
+$424,808 QoQ
Shares Held
46,887
+37.4% QoQ
Ownership
0.068%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 65.71331072578754.ToString("F0")%
Shared 0.ToString("F0")%
None 34.28668927421247.ToString("F0")%
Common Shares in RYTM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026SILVERCREST ASSET MANAGEMENT GROUP LLC holds $95,938,613 across 21 Biotechnology names. RYTM ranks #9 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VCEL |
Vericel Corp
|
959,207 | $30,857,689 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
15,963 | $8,356,151 | |
| 3 | MIRM |
Mirum Pharmaceuticals, Inc.
|
80,991 | $7,481,948 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
16,358 | $7,304,501 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
108,413 | $6,797,495 | |
| 6 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
163,633 | $5,943,150 | |
| 7 | PTGX |
Protagonist Therapeutics, Inc
|
47,931 | $5,051,927 | |
| 8 | ZYME |
Zymeworks Inc.
|
163,649 | $4,097,770 |
All Filings in RYTM
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,077,762 | 46,887 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,652,954 | 34,127 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,442,143 | 34,084 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $3,082,092 | 48,775 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||